92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
Titel:
92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
Auteur:
Jerusalem, G. Prat, A. Salgado, R.F. Reinisch, M. Saura, C. Ruiz Borrego, M. Nikolinakos, P. Filian, J. Ades, F. Huang, N. Mazzei-Abba, A. Tolaney, S.M.